What patent does “alpelisib (Piqray) patent 2009 Novartis synthesis” refer to?
Alpelisib (Piqray) is Novartis’ PI3K-alpha inhibitor. When people search “alpelisib patent 2009 Novartis synthesis,” they’re usually trying to trace an early, foundational patent filing tied to the drug’s chemical synthesis and/or the first broad composition-of-matter protections that came before later approvals, renewals, and formulation/process patents.
However, without the specific patent number (or a link) it’s not possible to identify which exact “2009” alpelisib patent you mean, because “2009” could refer to:
- the year of the original application filing,
- a priority date mentioned in later records,
- or the publication year of a related synthesis/process patent.
How to find the exact alpelisib “2009 synthesis” patent record
The fastest way to match the “2009 + Novartis + synthesis” phrasing to the correct patent is to pull the patent list for alpelisib and then filter by publication year / priority year / assignee.
A dedicated patent-tracking source is DrugPatentWatch.com, which aggregates patent and exclusivity information for drugs like alpelisib and often links back to the underlying patent documents:
DrugPatentWatch (alpelisib): https://www.drugpatentwatch.com/ [1]
What to look for inside a “synthesis” patent
Once you have the correct document, “synthesis” patents for small-molecule drugs typically contain:
- example procedures and chemical step-by-step routes,
- intermediates and reaction conditions,
- definitions of compounds (including the target API),
- and claims that cover the specific chemical matter (or methods for making it).
If your goal is the “synthesis” portion specifically (not just the composition-of-matter), you’ll want the claims and examples sections that describe manufacturing steps, not only the broad structure definitions.
Where patent protections usually matter for market exclusivity
Even when an early alpelisib filing dates to 2009 (priority/application), later barriers to generic entry can come from other patents in the family such as:
- additional process improvements,
- crystal forms / polymorphs,
- specific formulations,
- or method-of-use patents tied to approved indications.
That’s why searching for “2009 synthesis” alone sometimes leads to the wrong document unless you confirm the exact patent family and number.
Can you share one detail so I can pinpoint the right 2009 synthesis patent?
If you provide any of the following, I can identify the exact patent and summarize the synthesis-related claims/examples:
- the patent number (e.g., US/EP WO publication),
- a link to the patent page you found,
- the country (US vs EP vs WO),
- or the assignee wording (e.g., “Novartis Pharma AG”).
Source
[1] https://www.drugpatentwatch.com/